137 related articles for article (PubMed ID: 11739812)
1. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis.
Fusco C; Andreone V; Coppola G; Luongo V; Guerini F; Pace E; Florio C; Pirozzi G; Lanzillo R; Ferrante P; Vivo P; Mini M; Macrì M; Orefice G; Lombardi ML
Neurology; 2001 Dec; 57(11):1976-9. PubMed ID: 11739812
[TBL] [Abstract][Full Text] [Related]
2. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.
Samadzadeh S; Tabibian E; Sabokbar T; Shakoori A; Dehgolan SR; Armaki SA; Aslanbeigi B; Abolfazli R
J Neurol Sci; 2015 May; 352(1-2):37-40. PubMed ID: 25824849
[TBL] [Abstract][Full Text] [Related]
3. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
4. HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.
Mazdeh M; Taheri M; Sayad A; Bahram S; Omrani MD; Movafagh A; Inoko H; Akbari MT; Noroozi R; Hajilooi M; Solgi G
Pharmacogenomics; 2016 Apr; 17(5):489-98. PubMed ID: 27020477
[TBL] [Abstract][Full Text] [Related]
5. Considerations in the treatment of relapsing-remitting multiple sclerosis.
Calabresi PA
Neurology; 2002 Apr; 58(8 Suppl 4):S10-22. PubMed ID: 11971122
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
8. HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.
Comabella M; Fernández-Arquero M; Río J; Guinea A; Fernández M; Cenit MC; de la Concha EG; Montalban X
J Neuroimmunol; 2009 May; 210(1-2):116-9. PubMed ID: 19349081
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
10. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis: disease modifying therapy and the human leukocyte antigen.
Werneck LC; Lorenzoni PJ; Kay CSK; Scola RH
Arq Neuropsiquiatr; 2018 Oct; 76(10):697-704. PubMed ID: 30427510
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
13. Altered Immune Phenotypes and
Devi-Marulkar P; Moraes-Cabe C; Campagne P; Corre B; Meghraoui-Kheddar A; Bondet V; Llibre A; Duffy D; Maillart E; Papeix C; Pellegrini S; Michel F
Front Immunol; 2021; 12():628375. PubMed ID: 34113337
[TBL] [Abstract][Full Text] [Related]
14. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
[TBL] [Abstract][Full Text] [Related]
16. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
Matute-Blanch C; Río J; Villar LM; Midaglia L; Malhotra S; Álvarez-Cermeño JC; Vidal-Jordana A; Montalban X; Comabella M
J Neuroimmunol; 2017 Feb; 303():62-65. PubMed ID: 28063616
[TBL] [Abstract][Full Text] [Related]
17. Smoking affects the interferon beta treatment response in multiple sclerosis.
Petersen ER; Oturai AB; Koch-Henriksen N; Magyari M; Sørensen PS; Sellebjerg F; Søndergaard HB
Neurology; 2018 Feb; 90(7):e593-e600. PubMed ID: 29343473
[TBL] [Abstract][Full Text] [Related]
18. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
19. Mediterranean and Amerindian MHC class II alleles are associated with multiple sclerosis in Mexicans.
Aláez C; Corona T; Ruano L; Flores H; Loyola M; Gorodezky C
Acta Neurol Scand; 2005 Nov; 112(5):317-22. PubMed ID: 16218914
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of remitting forms of multiple sclerosis].
Lubetzki C
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):996-1000. PubMed ID: 11787366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
